Production (Stage)
Profound Medical Corp.
PROF
$5.13
$0.000.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 561.68% | 520.87% | 251.15% | 0.67% | -79.19% |
| Total Other Revenue | 26.28% | 20.44% | 24.89% | 19.33% | 32.38% |
| Total Revenue | 68.06% | 41.81% | 32.05% | 9.70% | -5.56% |
| Cost of Revenue | 34.02% | 23.83% | 33.10% | 7.53% | -16.75% |
| Gross Profit | 92.21% | 53.85% | 31.35% | 11.27% | 4.40% |
| SG&A Expenses | 38.70% | 24.68% | 35.08% | 17.58% | 8.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.00% | 21.80% | 29.00% | 11.39% | 0.39% |
| Operating Income | -23.77% | -16.77% | -28.25% | -11.80% | -1.86% |
| Income Before Tax | -14.27% | 0.87% | -9.15% | 1.47% | -5.25% |
| Income Tax Expenses | 100.00% | 99.22% | -97.39% | -146.75% | -144.74% |
| Earnings from Continuing Operations | -14.82% | 0.43% | -8.03% | 3.11% | -3.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.82% | 0.43% | -8.03% | 3.11% | -3.57% |
| EBIT | -23.77% | -16.77% | -28.25% | -11.80% | -1.86% |
| EBITDA | -24.74% | -17.15% | -29.15% | -12.24% | -2.62% |
| EPS Basic | 4.40% | 14.50% | 3.34% | 10.59% | 1.37% |
| Normalized Basic EPS | 4.93% | 14.92% | -7.21% | 0.07% | -10.65% |
| EPS Diluted | 4.62% | 14.68% | 3.13% | 10.38% | 1.15% |
| Normalized Diluted EPS | 4.93% | 14.92% | -7.21% | 0.07% | -10.65% |
| Average Basic Shares Outstanding | 18.94% | 16.89% | 12.35% | 9.02% | 5.58% |
| Average Diluted Shares Outstanding | 18.94% | 16.89% | 12.35% | 9.02% | 5.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |